共 43 条
- [1] Kolb HJ(2008)Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood 112 4371-4383
- [2] Green MR(2012)Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy Clin Cancer Res 18 1611-1618
- [3] Rodig S(2009)B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders Blood 114 2149-2158
- [4] Juszczynski P(2011)Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells Clin Cancer Res 17 4232-4244
- [5] Ouyang J(2015)Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials JAMA Oncol 1 433-440
- [6] Sinha P(2015)Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135
- [7] O'Donnell E(2015)PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N Engl J Med 372 311-319
- [8] Wilcox RA(2010)Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma Blood 116 3268-3277
- [9] Feldman AL(undefined)undefined undefined undefined undefined-undefined
- [10] Wada DA(undefined)undefined undefined undefined undefined-undefined